History

Ecnoglutide (development code XW003) was developed by Hangzhou Sciwind Biosciences as a long-acting, cAMP-biased GLP-1 analog; its discovery and preclinical pharmacology were published in Molecular Metabolism in 2023 (Guo et al.). Phase 2 and Phase 3 trials in type 2 diabetes and obesity read out across 2024-2026 in Nature Communications and The Lancet Diabetes & Endocrinology. China's NMPA approved ecnoglutide injection for type 2 diabetes on 30 January 2026 and for chronic weight management on 6 March 2026, with the developer describing it as the world's first approved cAMP-biased GLP-1 receptor agonist. A China-market commercialization collaboration with Pfizer China (up to roughly $495M in milestones) was announced 24 February 2026.

Ecnoglutide (development code XW003) is an injectable drug for type 2 diabetes and weight loss that belongs to the same broad GLP-1 receptor agonist family as semaglutide. It stands out for two reasons: its developer engineered it to be “cAMP-biased,” a real and characterized pharmacological property, and unlike many buzzy next-generation compounds it actually has peer-reviewed Phase 3 trials and regulatory approval. The catch is that the approval is China-only, all the pivotal efficacy data come from Chinese populations, and the marketing claim that the cAMP bias makes it clinically better than existing drugs has not been proven head-to-head in humans.

What it is

Ecnoglutide is a once-weekly subcutaneous peptide GLP-1 receptor agonist built from natural amino acids. It carries an Ala8→Val8 substitution and an 18-carbon fatty-acid conjugation at Lys30, which lets it bind albumin and circulate for days — giving it a steady-state half-life of roughly 124-138 hours that supports once-weekly dosing.

The headline engineering feature is “signaling bias.” When a GLP-1 receptor is activated it can trigger several downstream pathways; ecnoglutide is designed to favor cAMP induction while not strongly driving β-arrestin recruitment or receptor internalization. In cell assays it potently induced cAMP (a reported EC50 around 0.018 nM) without internalizing the receptor. The working hypothesis is that keeping receptors on the cell surface preserves and sustains the insulin-secreting and metabolic effects. The bias itself is genuine and characterized in the discovery paper — but whether that translates into better clinical results than ordinary, unbiased agonists is a mechanistic hypothesis, not an established fact.

The claims

The compound is marketed and discussed as a “next-generation” GLP-1 whose cAMP bias makes it superior to semaglutide and tirzepatide, and as a strong weight-loss and diabetes drug. Its approved and well-studied uses are glycemic control in type 2 diabetes and chronic weight management in overweight or obesity. Weaker, more speculative framings position the bias mechanism itself as a proven clinical advantage and treat any version available online as equivalent to the approved Chinese product.

A separate, recurring myth needs flagging because it circulates on some third-party sites: the claim that GLP-1 receptor agonists were moved to a prohibited “S4” class on the 2026 anti-doping list. That is false (see Legal and regulatory status below).

What the evidence actually shows

The human data are real and, by gray-market standards, unusually solid — multiple randomized trials, several peer-reviewed in major journals. The recurring limitation is that the pivotal efficacy data are essentially all from Chinese populations in sponsor-associated trials.

The pivotal obesity trial is SLIMMER (NCT05813795), a multicentre, randomized, double-blind, placebo-controlled study in 664 Chinese adults with overweight or obesity across 36 sites, testing once-weekly ecnoglutide at 1.2, 1.8, and 2.4 mg versus placebo (Lancet Diabetes & Endocrinology, 2025). Two distinct numbers are worth keeping straight, because earlier sources conflated them. The placebo-subtracted weight reduction at week 40 was about −9.1% (1.2 mg), −10.9% (1.8 mg), and −13.2% (2.4 mg) versus placebo; the mean absolute reduction from baseline at week 48 ranged up to roughly −15.4% at the top dose (the company release cites about 15.1% placebo-adjusted at the highest dose). Between 77.7% and 92.8% of participants across doses lost at least 5% of body weight, versus 16% on placebo. The effect was dose-dependent and reportedly had not plateaued. Most adverse events were mild-to-moderate gastrointestinal events.

On the diabetes side, a Phase 2 trial (Chinese registry CTR20211014, not an NCT number; 145 randomized, 20 weeks; Nature Communications, 2024) reported HbA1c reductions of −1.81% (0.4 mg) to −2.39% (1.2 mg) versus −0.55% on placebo, with modest weight change. The pivotal Phase 3 diabetes trial EECOH-1 (NCT05680155; 211 randomized, 24-week double-blind plus a 28-week extension; Nature Communications, 2026) found HbA1c reductions of −1.96% (0.6 mg) and −2.43% (1.2 mg) versus −0.87% on placebo, weight reductions around −3.0 to −3.2 kg, and up to about 80% of participants reaching HbA1c below 7%. A separate Phase 2b obesity trial in Australia and New Zealand (around 206 participants, 26 weeks, versus liraglutide 3.0 mg) reported robust weight loss but exists only as a 2022 company press release, so it carries less evidentiary weight than the peer-reviewed Phase 3 work.

Two things are worth being honest about. First, the discovery paper’s report that ecnoglutide produced greater weight reduction than semaglutide is rodent data — not a human comparison — and there is no head-to-head clinical trial against semaglutide or tirzepatide. The claimed clinical superiority of the cAMP-biased mechanism therefore remains unproven in people. Second, there is no credible evidence that ecnoglutide builds muscle. Like other GLP-1 agonists, the weight it removes includes some lean mass, and there is no human muscle or performance data for ecnoglutide specifically — the evidence there is thin to absent.

Legal and regulatory status

In China, the NMPA approved ecnoglutide injection for glycemic control in adults with type 2 diabetes on 30 January 2026 and for chronic weight management in adults with overweight or obesity on 6 March 2026. The developer describes it as the world’s first approved cAMP-biased GLP-1 receptor agonist. A China-market commercialization collaboration with Pfizer China was announced on 24 February 2026 (Sciwind retains manufacturing and marketing-authorization-holder status; Pfizer gets Mainland China commercialization rights; the deal is worth up to roughly $495M in milestones).

In the United States, ecnoglutide is not FDA-approved. No US registration trial readout or FDA filing was located, and the Pfizer collaboration is explicitly China-market only — so US or global availability should be treated as not established. Any “research-grade” or gray-market version sold outside the approved Chinese product is not an approved drug anywhere, is not quality-controlled, and is not legal for human use in the US or EU.

For athletes: GLP-1 receptor agonists are not prohibited by WADA. They sit on the WADA Monitoring Program — semaglutide was added in 2024 and tirzepatide for 2026, with the GLP-1 class carried into the 2026 in- and out-of-competition Monitoring Program (effective 1 January 2026, applied at the 2026 Winter Olympics). Monitoring is surveillance for misuse patterns, not a ban, and does not require a therapeutic use exemption. WADA has signaled a possible future listing decision (expected around end-2026 or 2027, ahead of LA 2028), but as of June 2026 GLP-1 agonists remain permitted. By class read-across, ecnoglutide would fall under the same monitoring category, not a prohibited class. The third-party claim that GLP-1 agonists were moved to a prohibited “S4” class in 2026 is false and contradicted by WADA’s own materials. For useful contrast, growth factors such as IGF-1 and mechano-growth factor (MGF) are prohibited under S2 (specifically S2.3, Growth Factors) at all times — but ecnoglutide is a GLP-1 analog, not a growth factor, so that prohibition does not apply to it.

Safety

The most consistent signal across the trials is dose-dependent gastrointestinal adverse events — nausea, diarrhea, and constipation — the typical GLP-1 class effect, mostly mild to moderate, with low rates of discontinuation driven by side effects in the published studies. Mild hypoglycemia was low and mostly seen in the diabetes setting; no severe hypoglycemia, pancreatitis, or deaths were reported in the published trials.

Beyond what these specific trials measured, the broader GLP-1 receptor agonist class carries label-level cautions that are reasonable to extrapolate but are not all confirmed for ecnoglutide individually: a boxed-warning rodent thyroid C-cell (medullary) tumor signal, with the class contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2; and reported risks of pancreatitis, gallbladder disease, lean-mass loss, and weight regain after stopping. Long-term safety and safety in non-Chinese populations are limited for ecnoglutide specifically — the pivotal trials were predominantly Chinese, with the obesity Phase 2b run in Australia and New Zealand. Nothing here is medical advice.

Bottom line

Ecnoglutide has a genuinely strong, peer-reviewed human evidence base — pivotal Phase 3 trials in both obesity and diabetes published in major journals, plus actual regulatory approval — which puts it well ahead of typical gray-market peptides. It does not reach “Strong human,” though, because all pivotal efficacy data are confined to Chinese populations, the approval is China-only with no FDA approval or located US program, and the marquee selling point — that the cAMP-biased mechanism makes it clinically better than semaglutide or tirzepatide — has never been tested head-to-head in humans. The weight-loss numbers are real but should be read carefully (placebo-subtracted versus absolute-from-baseline are different figures), and there is no evidence it builds muscle. Anything sold online outside the approved Chinese product is unapproved and unverified.

Evidence grade: Preliminary human.